Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Age
16–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects were 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)
Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1 (V1)
Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period
Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drug(s) (AEDs). Vagal nerve stimulation (VNS) was allowed and was not counted as a concomitant AED
You may not be if
History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3
History or presence of status epilepticus during the year preceding Visit 1 or during Baseline
Clareo Health | Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
